Aileron Therapeutics, Inc. ALRN
At closeJan 10, 2025, 4:00 PM EST
52-week range unavailable
- Market cap
- 45.72M
- Shares out
- 21.67M
- Forward P/E
- -1.22
- Volume
- 63.39K
- Open
- 1.97
- Previous close
- 2.11
- Day's range
- 1.96 – 2.17
- Beta
- 2.34
- Price target
- 13.00 (+516.1%)
Key statistics
- Enterprise value
- 85.27M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.54
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -12.07M
- Total cash
- 21.92M
- Total debt
- 0
- Return on equity
- -44.32%
- Short % of float
- 1.08%
- 50-day average
- 3.03
- 200-day average
- 3.47
Analyst view
- Target (low)
- 7.00
- Target (mean)
- 13.00
- Target (high)
- 19.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.48.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.25 | -0.27 | -0.02 | -8.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.25 | -0.45 | -0.20 | -80.00% |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.86 | — | — |
| Apr 15, 2024 | Dec 1, 2023 | 0.00 | -1.54 | — | — |
| Oct 13, 2023 | Sep 1, 2023 | 0.00 | -0.40 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | -0.39 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 18, 2024 | Ladenburg Thalmann | main | Buy | Buy |
| Dec 1, 2023 | Ladenburg Thalmann | up | Neutral | Buy |
About Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aileronrx.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ALRN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| UNIVERSITY OF TEXAS INVESTMENT MANAGEMENT | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 16, 2024 | 1,746,550 |
| WINDSOR JAMES BRIAN | Chief Executive Officer | Purchase | Dec 4, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| University of Texas/Texas AM Investment Managment Co | 6.48% | 1,403,339 | 3.05M | Sep 29, 2024 |
| Alyeska Investment Group, L.p. | 2.49% | 540,000 | 1.17M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 2.14% | 464,367 | 1.01M | Sep 29, 2024 |
| Vanguard Group Inc | 1.99% | 432,201 | 937.88K | Sep 29, 2024 |
| Cable Car Capital LLC | 1.94% | 420,000 | 911.40K | Sep 29, 2024 |
| Prosight Management, Lp | 1.72% | 372,157 | 807.58K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.94% | 419,427 | 910.16K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.51% | 111,248 | 241.41K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.21% | 45,857 | 99.51K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index ETF | 0.19% | 40,699 | 88.32K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.16% | 35,681 | 77.43K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 25,112 | 54.49K | Oct 30, 2024 |